Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.61 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | GSK3B | P49841 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6138764 | 0.96 | HDAC1 (0.66) | HDAC1HDAC8PDE4BHDAC3HDAC4 | |
| SCHEMBL3381070 | 0.94 | HDAC8 (0.69) | HDAC1HDAC8PDE4BHDAC3HDAC4 | |
| SCHEMBL7828372 | 0.94 | HDAC8 (0.69) | HDAC1HDAC8PDE4BHDAC3HDAC4 | |
| SCHEMBL3380464 | 0.89 | HDAC8 (0.71) | HDAC1HDAC8PDE4BHDAC3HDAC4 | |
| SCHEMBL100952 | 0.88 | NR4A2 (0.65) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL133319 | 0.87 | HDAC1 (0.75) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL6543556 | 0.85 | HAO1 (0.59) | HDAC1HDAC8PDE4BHDAC3HDAC4 | |
| SCHEMBL28761395 | 0.84 | HDAC1 (0.61) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL241664 | 0.83 | GSK3B (0.70) | HDAC1HDAC8HDAC3HDAC4HDAC7 | |
| SCHEMBL7865681 | 0.82 | SMN1; SMN2 (0.72) | HDAC1HDAC8HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112778117-A | Method for synthesizing 4- (4-fluorobenzoyl) butyric acid and analogue thereof in continuous flow microreactor | 江苏阿尔法药业有限公司 | 2021-05-11 | — | — | CN | disclosed |
| US-9072734-B2 | Quaternary ammonium salt compounds | TEIJIN PHARMA LIMITED (JP) | 2015-07-07 | — | — | US | disclosed |
| CN-102459231-B | Quaternary ammonium salt compound | TEIJIN PHARMA LTD | 2015-04-22 | — | — | CN | disclosed |
| CN-102796075-B | Benzocycloheptenes derivative as well as preparation method and medical application thereof | INST PHARM & TOXICOLOGY AMMS | 2014-03-12 | — | — | CN | disclosed |
| CN-101481323-B | Benzocycloheptenes derivatives, preparation method and medical application thereof | POISON MED INST PLA MED ACAD | 2013-11-20 | — | — | CN | disclosed |
| CN-102796075-A | Benzocycloheptenes derivative as well as preparation method and medical application thereof | INST PHARM & TOXICOLOGY AMMS | 2012-11-28 | — | — | CN | disclosed |
| CN-102459231-A | Quaternary ammonium salt compound | TEIJIN PHARMA LTD | 2012-05-16 | — | — | CN | disclosed |
| EP-2426121-A1 | QUATERNARY AMMONIUM SALT COMPOUND | Teijin Pharma Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | TEIJIN PHARMA LIMITED (JP) | 2012-02-23 | — | — | US | disclosed |
| CN-101842362-A | Benzothiazole compounds | INST MEDICAL W & E HALL | 2010-09-22 | — | — | CN | disclosed |
| EP-2193127-A1 | BENZOTHIAZOLE COMPOUNDS | The Walter and Eliza Hall Institute of Medical Research (AU) | 2010-06-09 | — | — | EP | disclosed |
| CN-101481323-A | Benzocycloheptenes derivatives, preparation method and medical application thereof | POISON MED INST PLA MED ACAD (CN) | 2009-07-15 | — | — | CN | disclosed |
| WO-2009039553-A1 | BENZOTHIAZOLE COMPOUNDS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2009-04-02 | — | — | WO | disclosed |
| US-6518273-B1 | 2-aryl indole derivative as antagonists of tachykinins | MERCK SHARP & DOHME LTD. | 2003-02-11 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000051984-A1 | 2-ARYL INDOLE DERIVATIVES AS ANTAGONISTS OF TACHYKININS | MERCK SHARP & DOHME LIMITED (GB) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| EP-0673367-A1 | 4-AMINOMETHYL/THIOMETHYL/SULFONYLMETHYL-4-PHENYLPIPERIDINES AS TACHYKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 1995-09-27 | — | — | EP | disclosed |
| EP-0673248-A1 | POTASSIUM CHANNEL ACTIVATORS FOR USE IN THERAPY | SMITHKLINE BEECHAM PLC (GB) | 1995-09-27 | — | — | EP | disclosed |
| WO-1994013292-A1 | POTASSIUM CHANNEL ACTIVATORS FOR USE IN THERAPY | SMITHKLINE BEECHAM PLC (GB) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | ADRB2, AGTR2, ADRB3 | HDAC1 583/4885HDAC8 1191/4885PDE4B 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.